Tagged as: Fresenius Kabi

Fresenius Kabi Files a Petition For Inter Partes Review of Amgen’s Pegfilgrastim Patent

On June 8, 2019, Fresenius Kabi filed a petition for inter partes review challenging the validity of U.S. Patent No. 9,643,997, entitled “Capture purification processes for proteins expressed in a non-mammalian system.”  The challenged claims in the patent, owned by Amgen Inc., relate to processes for purifying recombinant proteins expressed in a…

Read More